Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Rebuilder Medical Technologies is in concluding stages of finalizing a national contract to provide billing services for all physicians

Rebuilder Medical Technologies is in concluding stages of finalizing a national contract to provide billing services for all physicians

ReBuilder Medical Technologies reports 100% increase in second-quarter 2009 profits over first-quarter

ReBuilder Medical Technologies reports 100% increase in second-quarter 2009 profits over first-quarter

Significant drop in prevalence of rheumatoid vasculitis between 2000 and 2001

Significant drop in prevalence of rheumatoid vasculitis between 2000 and 2001

New online educational forum for medical professionals from HMP Communications

New online educational forum for medical professionals from HMP Communications

First-quarter financial results of ReBuilder Medical Technologies announced

First-quarter financial results of ReBuilder Medical Technologies announced

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

Electrodiagnostic and neuromuscular medicine featured at AANEM annual meeting

Electrodiagnostic and neuromuscular medicine featured at AANEM annual meeting

A new startup at California Nanosystems Institute

A new startup at California Nanosystems Institute

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Lyme disease emerging in Canada

Lyme disease emerging in Canada

Marijuana effectiveness as an HIV self-care strategy

Marijuana effectiveness as an HIV self-care strategy

New hope for warding off diabetes nerve loss

New hope for warding off diabetes nerve loss

Pregabalin shows potential as treatment for hot flashes

Pregabalin shows potential as treatment for hot flashes

Cimzia approved in U.S. for rheumatoid arthritis

Cimzia approved in U.S. for rheumatoid arthritis

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

Trial of Quadramet (153 Samarium-lexidronam) in combo with Velcade shows positive results

Trial of Quadramet (153 Samarium-lexidronam) in combo with Velcade shows positive results

Diabetics with previous foot ulcers may be able to participate in walking program

Diabetics with previous foot ulcers may be able to participate in walking program

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Discovery of MEDNIK syndrome

Discovery of MEDNIK syndrome